15 citations
,
February 2024 in “Journal of Dermatological Treatment” Dupilumab may help treat alopecia areata without needing high IgE levels.
2 citations
,
October 2023 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Dupilumab significantly improved a 5-year-old girl's prurigo nodularis without side effects.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib improves cicatricial alopecia and reduces key immune markers.
1 citations
,
November 2024 in “Neuro-Oncology” Temozolomide can cause severe bone marrow suppression, leading to life-threatening complications.
5 citations
,
December 2023 in “Clinical Case Reports” Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
April 2023 in “Journal of Investigative Dermatology” Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
7 citations
,
January 2019 in “Dermatology Online Journal” Ustekinumab treatment didn't prevent frontal fibrosing alopecia.
March 2010 in “Anti-inflammatory & anti-allergy agents in medicinal chemistry” Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
Combining excimer lamp and tofacitinib gel may help treat hair loss in children.
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
2 citations
,
October 2022 in “British journal of haematology” A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
1 citations
,
January 2026 in “International Journal of Dermatology” Dupilumab can cause unexpected scalp issues, so early symptom recognition is important to avoid hair loss.
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
September 2023 in “Journal of the American Academy of Dermatology” 1 citations
,
October 2024 in “QJM” IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.
October 2022 in “Portuguese journal of dermatology and venereology” Dupilumab led to complete hair regrowth and improved skin condition in a young man with severe eczema and hair loss.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
18 citations
,
January 2021 in “Theranostics” The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
May 2022 in “Journal of Neurology Neurosurgery & Psychiatry” Erenumab significantly reduced migraine days or severity in most patients after 3 months.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
9 citations
,
April 2024 in “The Oncologist” Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.
November 2020 in “Journal of The American Academy of Dermatology” Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.